Neurophet, a leading artificial intelligence (AI) solution company specializing in brain disease, is poised to unveil its state-of-the-art brain image analysis technology at the Radiological Society of North America 2023 (RSNA 2023) in Chicago, USA.
The company is preparing to showcase its flagship products, which include the brain MRI analysis software “Neurophet AQUA” and the brain PET scan analysis software “Neurophet SCALE PET”. Additionally, Neurophet will introduce analysis technology for infant brain images and cerebrovascular disease, with a specific focus on brain image analysis technology related to Alzheimer’s disease.
Attendees at the event will have the opportunity to experience the AI-powered brain image analysis technology, aimed at supporting the treatment of dementia and other brain diseases. Furthermore, Neurophet is gearing up to launch an ARIA (Amyloid-Related Imaging Abnormalities) analysis product next year, addressing potential side effects of Alzheimer’s disease treatments.
Neurophet’s participation at the RSNA will feature presentations at the AI Theater and Scientific Poster Session, where the company’s medical director will cover topics such as “How to be Prepared for the Real-World Amyloid Target Drug Prescriptions: ARIA, Amyloid Positivity and Beyond”. Additionally, a study titled “White Matter Lesion Asymmetry-An Indicator of Amyloid PET Positivity in Mild Cognitive Impairment Patients” will be presented at the Scientific Poster Session.
CEO Jake Junkil Been stated, “Neurophet has prepared demonstrations of various technologies to analyze infant brain images and cerebrovascular disease, which will be launched in the future. Based on our brain image analysis technology encompassing the entire spectrum of brain diseases, we are committed to achieving meaningful business results through intensified efforts in sales and marketing.”
The RSNA, renowned for bringing together experts and officials from academia, medicine, and industry to share the latest studies in radiology, serves as an influential platform for showcasing advancements in the field. This year, the RSNA celebrates its 109th anniversary and will host the event from November 26th to 30th, attracting professionals from around the world.
Founded in 2016, Neurophet aims to provide cutting-edge solutions for diagnosing, guiding treatment, and developing devices for brain diseases using AI technology. The company’s dedication to assisting patients suffering from brain diseases is evident in its array of products, including the brain MRI analysis software “Neurophet AQUA”, brain PET scan analysis software “Neurophet SCALE PET”, and other innovative tools for brain imaging.
Driven by expertise in neuroscience, Neurophet remains focused on exploring the human brain’s health and pioneering AI-based solutions for brain diseases, with a vision of improving the lives of patients worldwide.
(Source: Neurophet)
+ There are no comments
Add yours